Current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased overall survival (OS) compared with mitoxantrone (15.1 vs. 12.7 mo, HR 0.70, 95% CI 0.59-0.83, p < 0.0001). Furthermore, chemotherapy is not the only strategy available: several studies have shown as CRPC remains dependent on androgen receptor function for growth. Abiraterone acetate, an irreversible inhibitor of CYP17, has also been approved by FDA after docetaxel failure. In a phase III trial comparing abiraterone acetate to placebo, abiraterone showed improvement in OS (14.8 vs. 10.4 mo, HR 0.65, 95% CI 0.54-0.77; p < 0.0001). This review will discuss current options and the ongoing trials for second-line treatment of CRPC including chemotherapy, hormonal therapies, antiangiogenetic and immune strategies.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant / Altavilla, Amelia; Iacovelli, Roberto; Giuseppe, Procopio; Alesini, Daniele; Risi, Emanuela; Giuseppe Maria, Campenni; Palazzo, Antonella; Cortesi, Enrico. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 13:11(2012), pp. 1001-1008. [10.4161/cbt.21188]

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

ALTAVILLA, AMELIA;IACOVELLI, ROBERTO;ALESINI, DANIELE;RISI, EMANUELA;PALAZZO, ANTONELLA;CORTESI, Enrico
2012

Abstract

Current landscape of treatment of castration-resistant prostate cancer (CRPC) has recently changed. Cabazitaxel, a new taxane with potential antineoplastic activity, has been approved by Food and Drug Administration (FDA) after docetaxel failure. In a phase III trial, cabazitaxel showed increased overall survival (OS) compared with mitoxantrone (15.1 vs. 12.7 mo, HR 0.70, 95% CI 0.59-0.83, p < 0.0001). Furthermore, chemotherapy is not the only strategy available: several studies have shown as CRPC remains dependent on androgen receptor function for growth. Abiraterone acetate, an irreversible inhibitor of CYP17, has also been approved by FDA after docetaxel failure. In a phase III trial comparing abiraterone acetate to placebo, abiraterone showed improvement in OS (14.8 vs. 10.4 mo, HR 0.65, 95% CI 0.54-0.77; p < 0.0001). This review will discuss current options and the ongoing trials for second-line treatment of CRPC including chemotherapy, hormonal therapies, antiangiogenetic and immune strategies.
2012
second-line therapy; hormone therapy; sipuleucel-t; antiangiogenic therapy; tak 700; cabazitaxel; abiraterone acetate; mdv3100; chemotherapy; crpc
01 Pubblicazione su rivista::01a Articolo in rivista
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant / Altavilla, Amelia; Iacovelli, Roberto; Giuseppe, Procopio; Alesini, Daniele; Risi, Emanuela; Giuseppe Maria, Campenni; Palazzo, Antonella; Cortesi, Enrico. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - STAMPA. - 13:11(2012), pp. 1001-1008. [10.4161/cbt.21188]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/528641
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 6
social impact